title: Generation of lymphokine-activated killer cell activity by low-dose recombinant interleukin-2 and tumor cells.
abstract: The generation of lymphokine-activated killer (LAK) cells in vitro has been reported to require 100-1000 units of recombinant interleukin-2 (IL2). In this study we investigated the generation of human LAK cells with low-dose IL2 (1-10 U) in combination with human tumor cell lines. A significant LAK activity was generated within 3- to 5-days culture of PBL. Among six human tumor cell lines tested, the K562 cell line had the greatest stimulating activity, and the degree of cytotoxicity was comparative to that of PBL stimulated with higher doses of IL2 alone. The origin of this LAK activity was primarily the E(-) rosetting cell population. Cocultures of E- cells with 1 U/ml IL2 plus K562 had significantly higher cytotoxicity (P less than 0.05) compared to using E+ cells. Phenotypic analysis indicated that 1 U/ml IL2 plus K562 cell stimulation enhanced CD56+ and CD16+ cells. These studies suggest that very low dosages of IL2 with stimulator tumor cells can generate LAK activity comparable to that generated with high dosages of IL2 alone.
authors.affiliation: Division of Surgical Oncology, Jonsson Comprehensive Cancer Center, UCLA School of Medicine 90024.
authors.forename: S
authors.initials: S
authors.lastname: Yamamoto
authors.forename: D S
authors.initials: DS
authors.lastname: Hoon
authors.forename: P
authors.initials: P
authors.lastname: Chandler
authors.forename: I
authors.initials: I
authors.lastname: Schmid
authors.forename: R F
authors.initials: RF
authors.lastname: Irie
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D018801:CD2 Antigens; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007111:Immunity, Cellular; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000008:administration & dosage*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D004915:Leukemia, Erythroblastic, Acute / Q000276:immunology; D008213:Lymphocyte Activation; D016685:Mitomycin; D008937:Mitomycins / Q000494:pharmacology; D009369:Neoplasms / Q000276:immunology*; D011971:Receptors, Immunologic / Q000032:analysis; D014407:Tumor Cells, Cultured
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; D007376:Interleukin-2; D008937:Mitomycins; D011971:Receptors, Immunologic; D016685:Mitomycin